Welcome, Guest. Please login or register.
August 13, 2020, 08:05:25 am

Login with username, password and session length


  • Total Posts: 290
  • Total Topics: 149
  • Online Today: 23
  • Online Ever: 518
  • (January 21, 2020, 05:24:49 pm)
Users Online
Users: 0
Guests: 10
Total: 10


Welcome to the Cancer Health Forums, a round-the-clock discussion area for people who have any type of cancer, their friends and family and others with questions about living with cancer. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Cancer Health Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Show Posts

This section allows you to view all posts made by this member. Note that you can only see posts made in areas you currently have access to.

Topics - Cancer Health Editors

Pages: 1 [2] 3 4
The Food and Drug Administration (FDA) last week approved Kisqali (ribociclib) in combination with an aromatase inhibitor for first-line treatment of premenopausal and perimenopausal women with HR-positive/HER2-negative advanced breast cancer. It was also approved with Faslodex (fulvestrant) for postmenopausal women, either as initial treatment or after disease progression on hormone therapy.

This was the first drug to be approved using the FDA’s new Real-Time Oncology Review pilot program and Assessment Aid, with approval granted less than one month after submission of a supplemental New Drug Application.


First-line treatment with Tecentriq (atezolizumab) plus Alimta (pemetrexed) and platinum-based chemotherapy decreased the risk of disease progression or death in people with advanced non-small-cell lung cancer (NSCLC), according to an announcement from Genentech.

Results from the Phase III IMpower132 trial showed that the study met one of its primary endpoints, meaning the Tecentriq combination performed significantly better than chemotherapy alone and the difference was probably not attributable to chance. These results have not yet been presented at a scientific conference or published in a medical journal.


Advances against multiple myeloma have come at an especially rapid pace, with 10 new therapies approved in just the last 10 years. The arrival of a new generation of immunotherapies is accelerating progress even more.

Today, a range of immunotherapies—treatments that marshal the immune system to attack cancer—is available to patients with myeloma. Some are available to certain patients as standard therapy; others are being tested in clinical trials.

As a group, their impact “is greater than anything we’ve seen in myeloma,” says Nikhil Munshi, MD, director of Basic and Correlative Science at Dana-Farber’s Jerome Lipper Center for Multiple Myeloma.


In immunotherapy, the CAR T cells that square off against cancerous tumors face quite the Goliath: billions of tumor cells that have recruited healthy cells to help them repel an immune attack. But scientists at Fred Hutchinson Cancer Research Center have developed an inexpensive way to make tumors temporarily vulnerable. In recent work published in Cancer Research, the team used biodegradable liposome-based nanoparticles to carry immune-boosting drugs directly to solid tumors and open a window for CAR T cells to be more effective in preclinical models of breast and brain cancer.

The nanoparticles “are not supposed to replace conventional CAR T-cell therapy,” said Matthias Stephan, MD, PhD, who led the study. Instead, he envisions that “you could use these nanoparticles to precondition the patient, and precondition the tumor, so that your T cells work much better.”


Researchers have developed a new cutting-edge way to edit the genome of CD4 immune cells that is faster and more precise than currently used methods, The New York Times reports. While early research into this method has focused on manipulating immune cells to treat cancer or autoimmune disease, scientists believe it could be used to engineer HIV-resistant CD4 cells.

Currently, researchers in the gene-editing field commonly use a deactivated virus, known as a viral vector, to deliver genetic code into cells. In the HIV cure arena, scientists will, for example, draw stem cells that give rise to CD4 cells from an individual with the virus and use viral vectors to insert new genes into those cells that lack a key co-receptor on their surface to which HIV attaches in order to infect the cell. The scientists will then cultivate a large number of such stem cells, reinfuse them into the individual’s body and hope they flourish and populate the immune system with a long-lasting source of immune cells impervious to HIV’s assault.


A new method using CRISPR gene editing technology could allow scientists to create cancer-fighting T cells more easily, which could potentially increase their availability and reduce their cost, according to a study published this week in Nature.

“This is a rapid, flexible method that can be used to alter, enhance and reprogram T cells so we can give them the specificity we want to destroy cancer, recognize infections or tamp down the excessive immune response seen in autoimmune disease,” lead author Alex Marson, MD, PhD, of the University of California at San Francisco said in a UCSF press release.

Unlike traditional chemotherapy, which directly poisons cancer cells, immunotherapy helps the immune system recognize and fight cancer, usually by boosting the activity of T cells. One method uses a harmless virus to insert new genes into a patient’s T cells to make them express naturally occurring T-cell receptors (TCRs) that can recognize cancer antigens. Another technique, chimeric antigen receptor T-cell therapy, or CAR-T, uses a virus to insert artificial receptors that bind to cancer cells more readily than natural TCRs.


A year ago, Kelly Lamphere’s multiple myeloma was not responding to treatment, and her legs were so weakened by the cancer in her bones that she relied on a wheelchair and a walker. Today, because of CAR T-cell therapy, Lamphere’s disease is under control—and she can walk unaided again.

For most of 2017, Lamphere, 47, wasn’t sure how much time she had left. Her multiple myeloma, which for years had been stabilized by numerous chemotherapy regimens, along with a stem cell transplant in 2009, had begun outsmarting her treatment. Cancer built up in her bone marrow to the point where getting around was painful and tiring. While doctors near Lamphere’s home outside Syracuse, New York, sought other treatment possibilities, it was apparent to her she was running out of options.

Then, in August 2017, Lamphere received a phone call that changed everything.


In March 2014, Robert Johnson had already been told he’d run out of options for treatment of his stage IV adenocarcinoma non-small cell lung cancer. But a referral to Dana-Farber Cancer Institute’s Lowe Center for Thoracic Oncology connected him with an early immunotherapy clinical trial that sent him into remission—a remission that’s still holding more than 3 ½ years on.

Johnson’s medical journey started in March 2012, when the 56-year-old Long Island resident was recovering from hip replacement surgery. Searing pain in his right flank sent him to the emergency room, which he thought might be kidney stones. A CAT scan revealed otherwise: His lymph nodes under his ribs were enlarged. A biopsy determined that Johnson had stage 3B adenocarcinoma non-small cell lung cancer.


Cyramza (ramucirumab), a type of targeted therapy that slows tumor growth, led to improved overall survival and delayed disease progression in people with hepatocellular carcinoma (HCC), according to study results presented at the American Society of Clinical Oncology annual meeting last month in Chicago.

Second-line treatment with Cyramza extended the median survival by only about a month compared with placebo in the REACH-2 trial, but the proportion of patients who were still alive 18 months after starting therapy more than doubled, from about 11 percent to 25 percent.


First-line treatment with the checkpoint inhibitor Tecentriq (atezolizumab) plus chemotherapy reduced the risk of disease progression or death for women with metastatic or locally advanced triple-negative breast cancer (TNBC), according to late-stage clinical trial results recently announced by Genentech, a Roche company.

Interim study data also showed an “encouraging” overall survival benefit for a subset of women with a favorable biomarker, the company said. These results have not yet been presented at a scientific conference or published in a medical journal.

The findings come from the IMpassion130 trial, a Phase III randomized, double-blind study evaluating the safety and efficacy of Tecentriq plus Abraxane (nab-paclitaxel), an albumin-bound formulation of the widely used chemotherapy drug, for patients with locally advanced or metastatic (spread beyond the breast) TNBC.


When Acra Samuels flew from Montana, to be examined at Dana-Farber in 2016, her colon and liver were dotted with recurring tumors that seemed unstoppable. One doctor had forecast she had no more than six months to live.

At Dana-Farber/Brigham and Women’s Cancer Center, surgeon Monica Bertagnolli, MD, removed a portion of the 46-year-old woman’s cancerous colon.

While Samuels recovered in the hospital, George Demetri, MD, director of Dana-Farber’s Center for Sarcoma and Bone Oncology, asked Michael Nathenson, MD, to order a DNA sequencing test of her tumor, which appeared to be a sarcoma—a cancer of soft or connective tissue—but whose exact type wasn’t immediately clear.


In 2017, Keith Rohleder was diagnosed with a rare, aggressive blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN), which most people have never heard of. Even most physicians—including many oncologists—know little about the disease. But thanks to Rohleder and his caregivers, that is beginning to change.

BPDCN occurs in the bone marrow and blood. The BPDCN Center at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) is one of the first facilities in the U.S. to focus on care and research of the disease, and Rohleder was one of a dozen DF/BWCC patients to take part in a recent clinical trial.


Molecular profiling can provide clinically meaningful information to help people with pancreatic cancer and their providers select effective treatments, the Pancreatic Cancer Action Network (PanCAN) announced last week.

Results from a study published in the American Association for Cancer Research journal, Clinical Cancer Research, showed that pancreatic cancer patients who had “actionable” mutations and received matched targeted therapy had better outcomes than those who did not.

“There has been a longstanding notion that precision medicine cannot benefit pancreatic cancer patients,” said study coauthor and PanCAN chief science officer Lynn Matrisian, PhD, MBA. “We now have to rethink that position as this research exemplifies a changing tide in the way we should treat pancreatic cancer patients, ensuring molecular profiling is an integral part of their treatment journey.”


In a new study published online June 25, 2018 in Nature Medicine, University of California San Francisco researchers have identified a key biological pathway in human cancer patients that appears to prime the immune system for a successful response to immunotherapy drugs known as checkpoint inhibitors. The findings, including initial observations from human tumor samples, mechanistic studies in mouse models, then confirmation in additional patient samples, could better enable clinicians to predict which patients will naturally benefit from these promising new treatments, and potentially to modify the immune response in other patients to allow more people to benefit from these therapies.


Off Topic Forum / Share Your Story!
« on: June 28, 2018, 04:38:55 pm »
Want to be featured in a future issue of Cancer Health? Share your story here (https://www.cancerhealth.com/iframe/cancer-health-stories-form) and you will appear in our Cancer Health Stories (https://www.cancerhealth.com/category/cancer-health-stories) online. You might even make it into a future issue of the magazine!

Pages: 1 [2] 3 4

© 2020 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.